Testing IFO/Mesna and VP-16 Combination Therapy in the P388 Leukemia Model

Publisher Website
Google Scholar
Abstract
Summary(1) The therapeutic effect of a combination of IFO/mesna and VP-16 can be considered synergistic when compared with the effects obtained when a single agent is given in optimal dose. The number of 60-day survivors is significantly increased.(2) The rapidly growing lymphatic leukemia P388 is a suitable model for testing combination therapy approaches.(3) Dose optimization to Box-Wilson is a promising method both economically and from the ethical standpoint.

This publication has 0 references indexed in Scilit: